Combo Therapy for Advanced NSCLC Provides PFS Benefit

Patricia McKnight

December 19, 2022

The study covered in this summary was published on as a preprint and has not yet been peer reviewed.

Key Takeaway

  • In patients with epidermal growth factor receptor (EGFR) TP53-mutated non–small cell lung cancer (NSCLC), combining a tyrosine kinase inhibitor (TKI) with antiangiogenic therapy or chemotherapy led to better progression-free survival (PFS) than a TKI alone.

Why This Matters

  • Typically, these patients have a poor prognosis.

  • Adding an antiangiogenic agent or chemotherapy to TKI therapy may prolong the PFS in this patient population.

Study Design

  • The study included 124 patients with advanced NSCLC as well as EGFR and TP53 mutations from a single center in China.

  • Overall, 72 patients received EGFR-TKIs combined with antiangiogenic drugs (22 patients) or chemotherapy (50 patients). Among those who were given an antiangiogenic agent, 12 received anlotinib, and 10 received bevacizumab.

  • The remaining 52 patients underwent EGFR-TKI monotherapy.

  • The primary endpoint was PFS.

Key Results

  • The median PFS was significantly longer in the combination therapy group (18.0 months vs 7.0 months; P < .001).

  • In the combination group, 89% of patients were alive and progression-free at the 6-month mark, compared with 71% in the EGFR-TKI group.

  • At 12 months, the rates were 62% in the combination group and 24% in the monotherapy group.


  • The study was retrospective, and few patients had BRAC1 and MYC mutations compared with other mutations

  • The authors used a single accrual center for data collection.

  • The study did not report adverse effects, owing to incomplete medical records.


  • The study was supported by the National Natural Science Foundation of China.

  • The authors did not report any conflicts of interest.

This is a summary of a preprint research study, "Optimal Therapy for Concomitant EGFR and TP53 Mutated Non–Small Cell Lung Cancer: A Real-world Study." The study has not been peer reviewed. The full text can be found at

For more news, follow Medscape on Facebook, Twitter, Instagram, and YouTube.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.